Evidence map›Paper›PMID 35335081›Full record

ArticleVaccines2022

Effectiveness of Monovalent Rotavirus Vaccine in Mozambique, a Country with a High Burden of Chronic Malnutrition.

Assucênio Chissaque, Rachel M Burke, Esperança L Guimarães, Filomena Manjate, Arsénio Nhacolo, Jorfélia Chilaúle, Benilde Munlela, Percina Chirinda, Jerónimo S Langa, Idalécia Cossa-Moiane and 14 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The Full Impact of Rotavirus Vaccines in Africa Has Yet to Be Realized.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 5 countries.

Assucênio ChissaqueInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.ORCID 0000-0002-9470-6068
Rachel M BurkeCenters for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0002-5678-5826
Esperança L GuimarãesInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.
Filomena ManjateInstituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa, Rua da Junqueira 100, 1349-008 Lisboa, Portugal.ORCID 0000-0003-3632-2047
Arsénio NhacoloCentro de Investigação em Saúde de Manhiça (CISM), Maputo 1929, Mozambique.
Jorfélia ChilaúleInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.
Benilde MunlelaInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.
Percina ChirindaCentro de Investigação em Saúde de Manhiça (CISM), Maputo 1929, Mozambique.ORCID 0000-0002-2649-1034
Jerónimo S LangaInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.
Idalécia Cossa-MoianeInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.
Elda AnapakalaInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.
Adilson Fernando Loforte BauhoferInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.ORCID 0000-0001-8184-9695
Marcelino GarrineCentro de Investigação em Saúde de Manhiça (CISM), Maputo 1929, Mozambique.ORCID 0000-0002-8619-8761
Eva D JoãoCentro de Investigação em Saúde de Manhiça (CISM), Maputo 1929, Mozambique.
Júlia SamboInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.ORCID 0000-0002-4246-7085
Luzia GonçalvesGlobal Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa (UNL), 1349-008 Lisbon, Portugal.ORCID 0000-0002-9710-1945
Goitom WeldegebrielWorld Health Organization Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Keith ShabaWorld Health Organization Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Isah Mohammed BelloWorld Health Organization Regional Office for Africa, Brazzaville P.O. Box 06, Congo.ORCID 0000-0001-6351-7080
Jason M MwendaWorld Health Organization Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Umesh D ParasharCenters for Disease Control and Prevention, Atlanta, GA 30329, USA.
Jacqueline E TateCenters for Disease Control and Prevention, Atlanta, GA 30329, USA.
Inácio MandomandoInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.ORCID 0000-0002-1078-2187
Nilsa de DeusInstituto Nacional de Saúde (INS), EN1, Bairro da Vila-Parcela nº 3943, Distrito de Marracuene, Maputo 264, Mozambique.
Instituto Nacional de Saúde · MZManhiça Health Research Centre · MZWorld Health Organization Regional Office for Africa · CGCenters for Disease Control and Prevention · USEduardo Mondlane University · MZUniversity of Lisbon · PT

Funding

CDC HHS CDCDeutsche Forschungsgemeinschaft JO369/5-1United States Agency for International Development AID-656-F-16-00002World Health Organization 001World Health Organization (WHO / AFRO)
6 · The paper itself

Abstract

Mozambique introduced monovalent rotavirus vaccine (Rotarix®) in September 2015. We evaluated the effectiveness of Rotarix® under conditions of routine use in Mozambican children hospitalized with acute gastroenteritis (AGE). A test negative case-control analysis was performed on data collected during 2017−2019 from children <5 years old, admitted with AGE in seven sentinel hospital sites in Mozambique. Adjusted VE was calculated for ≥1 dose of vaccine vs. zero doses using unconditional logistic regression, where VE = (1 − aOR) × 100%. VE estimates were stratified by age group, AGE severity, malnutrition, and genotype. Among 689 children eligible for analysis, 23.7% were rotavirus positive (cases) and 76.3% were negative (controls). The adjusted VE of ≥1 dose in children aged 6−11 months was 52.0% (95% CI, −11, 79), and −24.0% (95% CI, −459, 62) among children aged 12−23 months. Estimated VE was lower in stunted than non-stunted children (14% (95% CI, −138, 66) vs. 59% (95% CI, −125, 91)). Rotavirus vaccination appeared moderately effective against rotavirus gastroenteritis hospitalization in young Mozambican children. VE point estimates were lower in older and stunted children, although confidence intervals were wide and overlapped across strata. These findings provide additional evidence for other high-mortality countries considering rotavirus vaccine introduction.

Indexed as

childrengastroenteritismalnutritionMozambiquerotavirusvaccine effectiveness

Identifiers

PMID35335081
PMCPMC8953339
OpenAlexW4220907893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.